Register Before May 31 & Save Up To $700

August 27-29, 2019 | San Diego, CA

www.ipf-summit.com

3rd Annual IPF Summit 2019

Overcome Translational Challenges in the Development of Truly Curative IPF Drugs

Keynote Speakers:

Fernando Martinez
Executive Vice Chair of Medicine
Weill Cornell Medical College

Ganesh Raghu
Director, Interstitial Lung Disease/ Sarcoid, Pulmonary Fibrosis Program
University of Washington

Toby Maher
Professor of Interstitial Lung Disease
Imperial College London

And 28 other expert speakers including:

Joe Arron
Senior Director, Immunology Research
Genentech

Eric Lefebvre
Chief Medical Officer
Pliant Therapeutics

Bernt van den Blink
Senior Medical Director
Promedior

Elias Kouchakji
Senior Vice President, Clinical Development, Drug Safety & Pharmacovigilance
FibroGen

Majd Mouded
Medical Director, Clinical Development
Biogen

31 speakers | 2 Streams | 3 Workshops | 150+ Attendees | 15 Hours of Networking

Partners: 4Dx | monARC BIONETWORKS *Empowered Patients, Faster Cures* | XYLYX

Tel: +1 617 455 4188 **Mail:** Info@hansonwade.com @focusSeries

hansonwade

Welcome to the World's Largest Gathering of IPF Drug Developers

Confidently Close the Translational Gap, Design & Execute More Efficient Clinical Trials & Understand Biomarkers Best to Optimize Your IPF Drug Development

The **3rd IPF Summit** is the only discussion and networking forum exclusively helping pharma and biotech **tackle the lack of preclinical predictability** and **corresponding clinical attrition in IPF drug development.**

Developed in combination with 30 stakeholders including **Promedior**, **Biogen**, **Genentech**, **Celgene** and **AstraZeneca** this intimate summit will once again pre-competitively advance the field beyond empirical data and more confidently translate IPF candidates through drug development pipelines.

Across **two parallel tracks** of learning hear world class insights on translational roadblocks, including: treating progressive fibrosing ILD as a parallel to IPF, understanding SSc-ILD as a path for proof of concept, and evaluating cellular senescence as a new pathological feature for target identification.

Join **150 IPF drug developers** at this unique and highly focused forum and equip your team with the knowledge and connections to advance your next 12 months of IPF R&D.

> "This is my 3rd Hanson Wade conference and I have left each time very satisfied having considerably improved my knowledge base and meeting some serious experts in the field"
> Daichii Sankyo

> "I like Hanson Wade's way of putting together smaller, but more specific meetings. It's definitely my favorite and I'm coming back next year"
> EMD Serono

> "The conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics"
> AstraZeneca

> "Very targeted meeting filled with KOLs and industry leaders in this exciting field. Meeting organized and run better than any other conference I have attended"
> Intellicyt

Join the Preclinical Stream to Understand:

- Challenges in dissecting protective from disease driving cell senescence with Cedars-Sinai Medical Center to **inform senolytic therapies and attenuate fibrosis**
- Target identification beyond bleomycin and better modelling of fibrotic lung disease *in vitro* with XYLYX Bio to **better identify targets and track results into the clinic**
- Updates on targeting lysyl oxidase like 2, toll-like receptor 5, oxylipin metabolism and harnessing miR-29 mimics from leading biotech's to **evaluate the next generation therapeutic landscape**
- Overlap between IPF and other fibrotic diseases with Merck to **explore a common regulator of fibrosis**

Join the Clinical Stream to Evaluate:

- Transforming patient data into actionable insights with monARC Bionetworks to **decentralize clinical trials and decrease patient burden**
- Optimal design of early and late stage IPF studies with Imperial College London to **navigate clinical trials in an era of approved therapies**
- Share scientific rationale and strategic considerations for partnerships in IPF with pharma to **more quickly accelerate promising innovations**
- Adding radiology to the pulmonary fibrosis equation with Mount Sinai and using systemic biomarkers to **give mechanistic understanding in the context of clinical trials**

What Previous IPF Summit Attendees Thought:

"The first IPF summit was extremely successful. It allowed for industry and academics to interact over discussions of pathogenesis, biomarkers and clinical trial challenges. As the field continues to evolve, this forum is increasingly important to continue to facilitate those discussions...This was the best pragmatic development conference for pulmonary fibrosis that I have been too"

Biogen

"Great meeting where I learned a lot and met a lot of thought leaders and colleagues in the field who are trying to think through similar development questions"

ACCELERON PHARMA

"I found the conference very interesting. It was well organized and I like that it was small because it fostered a lot of discussion. The networking periods were extremely helpful and the speed networking was the highlight of the conference. I would love to have done a second round to meet the rest of the people and hear more about their work"

MatTek CORPORATION

"All the speakers were superb, and every session provided novel and important insight regarding IPF. The effort the speakers put into their presentations was evident. Great job"

CEDARS-SINAI

"The agenda covered key research and clinical aspects of IPF. The speakers clearly acknowledged the challenges of this disease and there was a clear spirit and willingness from the participants to openly discuss these challenges and suggest possible solutions"

Boehringer Ingelheim

"This disease specific conference was informative - by planning a concentrated topic it gave an opportunity to look at IPF through a tighter lens"

Genentech
A Member of the Roche Group

Your 31 Expert Speakers

Your Keynotes:

Fernando Martinez
Chief, Division of Pulmonary & Critical Care Medicine
Weill Cornell Medicine

Ganesh Raghu
Director, Interstitial Lung Disease/ Sarcoid, Pulmonary Fibrosis Program
University of Washington

Toby Maher
Professor of Interstitial Lung Disease
Imperial College London

Your 28 other expert speakers:

Ahmet Tutuncu
Executive Vice President, Clinical & Regulatory
Respivant

Andrei Gudkov
Professor of Oncology
Roswell Park Comprehensive Cancer Center

Bernt van den Blink
Senior Medical Director
Promedior

Cory Hogaboam
Professor of Medicine
Cedars-Sinai Medical Center

Dan Rose
Steering Committee
Clinical Trials Transformative Initiative

Elias Kouchakji
Senior Vice President, Clinical Development, Drug Safety & Pharmacovigilance
FibroGen

Eric Lefebvre
Chief Medical Officer
Pliant Therapeutics

Hans Brightbill
Scientific Manager, Translational Immunology
Genentech

Harry Karmouty-Quintana
Assistant Professor, Department of Biochemistry and Molecular Biology
UTHealth - McGovern Medical School

Jane Connor
Associate Director
AstraZeneca

Joe Arron
Senior Scientist & Senior Director – Immunology Discovery
Genentech

John O'Neill
Chief Scientific Officer
XYLYX

Karl Kossen
Senior Vice President of Translational Science
Indalo Therapeutics

Kevin Flaherty
Division of Pulmonary & Critical Care Medicine
University of Michigan

Komathi Stem
Founder & Chief Executive Officer
monARC Bionetworks

Majd Mouded
Medical Director, Clinical Development
Biogen

Marc Ramis-Castelltort
Co-Founder & Chief Executive Officer
Senolytic Therapeutics

Mary Salvatore
Associate Professor – Thoracic Radiology
Mount Sinai Medical Center

Mehran Moghaddam
Chief Executive Officer
OROX BioSciences

Peter Schafer
Executive Director, Translational Development
Celgene

Rick Jack
President, Chief Operations Officer & Chief Scientific Officer
Promedior

Robert Kaner
Associate Professor of Clinical Medicine
Weill Cornell

Rusty Montgomery
Director, Research
Miragen Therapeutics

Sonya Zabludoff
Senior Director
Nitto Denko

Stavros Garantziotis
Medical Director, Clinical Research Unit
National Institute of Environmental Health Sciences

Sunhwa Kim
Principal Scientist
Merck

Wolfgang Jarolimek
Head of Drug Discovery
Pharmaxis

Yves Wyckmans
Senior Director, Corporate Business Development & Strategic Planning at Actelion
Janssen Pharmaceuticals

"This conference was of outstanding value. First in class presentations, great opportunity for networking and perfect logstics"

AstraZeneca

Hear from the IPF Summit speakers:

"The explosive advance in the understanding of disease mechanisms and putative targets in IPF necessitates an annual meeting of key opinion leaders in academia and industry. The IPF Summit is an ideal meeting to remain current with all of these advances!"

Cory Hogaboam
Professor of Medicine
Cedars-Sinai Medical Center

Workshop Day
Tuesday, August 27

Workshop A
9.00am - 12.00pm

Overlap Between IPF & Other Fibrotic Diseases: Pathophysiology & Target Identification in Fibrosis

With better screens and better tools giving better outcomes, critically assessing molecular prognostic biomarkers of fibrosis can inform an arsenal of non-invasive techniques and innovate drug development.

This workshop will explore:

- Overlap and relationships between organ-specific pathological fibrosis
- Common pathways to different organ-specific fibrosis; is there a central regulator of fibrosis across several organs that we can target?
- Combination therapy to treat fibrosis; specifically, bi-functional molecules regulating both inflammation and fibrosis

Workshop Leader

Sunhwa Kim
Principal Scientist
Merck

Workshop B
12.30pm - 3.30pm

Adding Radiology to the Pulmonary Fibrosis Equation

Advancements in the application of imaging techniques to inform and enrich clinical trial decisions goes hand-in-hand with the next generation of IPF drug development.

Following on from last IPF Summit's workshop, continue the conversation on imaging's capacity to:

- Advance biomarker identification
- Differentially diagnoses patients
- Improve clinical translation

Workshop Leader

Mary Salvatore
Associate Professor – Thoracic Radiology
Mount Sinai Medical Center

Workshop C
4.00pm - 7.00pm

Working Meeting of the Prognostic Lung Fibrosis Consortium (PROLIFIC)

As clinical trial activity gears up, developing well-characterized assays to determine clinical utility and commercial potential of current predictive or prognostic biomarkers is becoming increasingly important.

This expert led meeting will cover:

- Evaluation of additional inflammation markers for the PROLIFIC list
- Update on Clinical Testing Laboratories selection and contracting process
- Execution of the collaboration agreement

Workshop Leader

Peter Schafer
Executive Director, Translational Development
Celgene

Conference Day One
Wednesday, August 28

Fernando Martinez
Chief, Division of Pulmonary & Critical Care Medicine
Weill Cornell Medicine

7.50 Chair's Opening Remarks

Reviewing the Last 12 Months of IPF Drug Development

Fernando Martinez
Chief, Division of Pulmonary & Critical Care Medicine
Weill Cornell Medicine

8.00 What Are the Clinical Issues & Developments in the Last 12 Months of IPF Drug Development?

- Highlighting progress form the IPF Summit 2017 and 2018
- Reviewing the IPF drug development landscape
- Outlining outcomes for the 3rd IPF Summit from the outset

Peter Schafer
Executive Director, Translational Development
Celgene

8.30 The Prognostic Lung Fibrosis Consortium (PROLIFIC)

- Developing well-qualified assays for important peripheral blood markers of pulmonary fibrosis, suitable for non-exclusive use as prognostic or predictive biomarkers within the context of clinical trials, and for potential commercial use
- Overviewing the most important pulmonary fibrosis serum or plasma biomarkers based on prognosis (progression-free survival and/or lung function), through a survey of the literature and relevant research

4Dx

9.00 How Much More Data has Been Generated to Support Imaging Modalities?

- Talk details to be finalized by 4Dx

9.30 Speed Networking

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the IPF field and establish meaningful business relationships.

10.15 Morning Break & Networking

Preclinical Stream

Chair:
Jane Connor, Associate Director, **AstraZeneca**

Pulmonary Pathobiology for New Target Identification

11.00 Toll-Like Receptor 5 (TLR5) Agonism as a Novel Immunotherapy Modality in IPF

- Outlining the role of host defence and immune pathways (e.g. muc5b and TOLLIP) as risk factors on IPF pathogenesis and identification of TLR5 as a novel, druggable target in IPF
- Demonstrating TLR5 relationship with IPF in humans and in mice
- Analyzing human and murine data to hypothesize TLR5 agonism is effective in preventing and treating lung fibrosis

Stavros Garantziotis, Medical Director, Clinical Research Unit, **National Institute of Environmental Health Sciences**

Clinical Stream

Chair:
Ganesh Raghu, Director, Interstitial Lung Disease/ Sarcoid, Pulmonary Fibrosis Program, **University of Washington**

Transforming Patient Data into Actionable Insights

11.00 Optimal Design of Early & Late Phase IPF Studies

- Refining endpoints for early stage studies to reduce the attrition rate for clinical trials
- More talk details to follow

Toby Maher, Professor of Interstitial Lung Disease, **Imperial College London**

11.30 Disruption of Oxylipin Metabolism using Designed Multiple Ligand (DML) Molecules to Treat IPF

- Discovery and development of small molecules with multiple ligands to treat IPF
- Sharing soluble epoxide hydrolase (sEH) as a target for IPF and secondary targets selected based on their potential role in alleviating fibrosis
- Presenting recently generated new pharmacology data in the Bleomycin mouse model for IPF

Mehran Moghaddam, Chief Executive Officer, **OROX BioSciences**

11.30 Patient Engagement, Use of Mobile Devices in Clinical Research, & Decentralized Clinical Trials

- Decreasing the costs of clinical trials by increasing patient engagement meaning enhanced recruitment, fewer amendments, improved retention, and better patient experience
- Using mobile devices to improve the quality and efficiency of trials and reflect more accurately "real world data"
- Decentralizing trials to decrease the patient burden, enroll a more diverse, representative spectrum of patients, and address challenges for investigative sites

Dan Rose, Steering Committee, **Clinical Trials Transformative Initiative**

12.00 Disease-Specific Extracellular Matrix Cell Culture Substrates to Improve Predictive *in Vitro* Models of Pulmonary Fibrosis

- Developing much-needed commercial research tools for IPF research in the form of a standardized, fully humanized 3D cell culture platform comprised of intact extracellular matrix (ECM) that recapitulates the human IPF disease environment *in vitro*
- Reducing dependence on animal models, and enabling more meaningful and relevant results

John O'Neill, Chief Scientific Officer, **XYLYX**

12.00 Real-World Data: Transforming Clinical Research in IPF

- Describing opportunities to utilize Real-World Data in IPF clinical research
- Exploring Real-World Data considerations unique to IPF
- Demonstrating approaches to Real-World Data to accelerate IPF research

Komathi Stem, Founder & Chief Executive Officer, **monARC Bionetworks**

12.15 Lunch & Networking

Closing the Translational Gap

1.15 Looking at the Kinetics of Transcriptional & Extracellular Matrix Responses to Bleomycin Induced Lung Fibrosis

- Differentiating intratracheal versus systemic Bleomycin models through transcriptome changes
- Using mass spectrometry analysis of extracellular matrix and lung imaging to quantify preclinical disease outcomes

Hans Brightbill, Scientific Manager, Translational Immunology, **Genentech**

1.45 Can we Correlate Biochemical Measurements & Pulmonary Function?

- Analyzing preclinical lung mechanics and the future of drug development
- Presenting sensitivity and clinical relevance of lung function measurements mice
- Understanding lung function and imaging in mice as new requisites for drug development for pulmonary fibrosis

Harry Karmouty-Quintana, Assistant Professor, Department of Biochemistry & Molecular Biology, **UTHealth - McGovern Medical School**

Translating Patient Activity into Endpoints

1.15 Six-Minute Walk as Secondary Endpoint in IPF

- Reviewing open label data
- Contextualizing data to 6 minute walk time distance (6MWTD)
- Moving forward in IPF clinical trials using 6MWTD

Bernt van den Blink, Senior Medical Director, **Promedior**

Rick Jack, President, Chief Operations Officer & Chief Scientific Officer, **Promedior**

1.45 Refractory Cough as Primary Endpoint in IPF: Update on Inhaled RVT-1601

- Disucssing unmet need for symptom relief and quality of life improvement in IPF patients
- Bringing fresh life to an old drug
- Updating on Inhaled RVT-1601: from proof of concept to Phase 2b

Ahmet Tutuncu, Executive Vice President, Clinical & Regulatory, **Respivant**

2.15 Afternoon Break & Networking

Prognostic, Diagnostic, Therapeutic, Enrichment: Biomarker Updates in IPF

Mary Salvatore
Associate Professor – Thoracic Radiology
Mount Sinai Medical Center

3.15 The Intersection of Lung Cancer & Fibrosis – as Told Through Imaging

- Discussing overlap of lung fibrosis with fibrosis seen in lung cancer
- Mapping out how orphan lung cancer develops from fibrosis with CT scanning

Toby Maher
Professor of Interstitial Lung Disease
Imperial College London

3.45 Using Systemic Biomarkers in the Context of Clinical Trials to Give Mechanistic Understanding

- Updates on the PROLIE Study: a biomarker cohort as a vehicle to discover and validate biomarkers including blood based measures
- Sharing efforts with AI to improve reading of CT scans and introduce as clinical trial endpoints
- Developing strategies to increase confidence that drugs are hitting mechanism and interfering with fibrotic pathways

4.15 Chair's Closing Remarks

4.30 Scientific Poster Session

After the formal presentations have finished, the learning and networking carries on. The Poster Session allows you to present your research, connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.

"The IPF Summit provides an excellent venue for scientific updates and networking not seen at other conferences. The speakers and format allow for a wonderful few days of focused discussions with easy access to all participants that are eager to engage. Looking forward to attending again this year!"

Rusty Montgomery
Director – Research
Miragen Therapeutics

"I'm looking forward to great scientific discussion with colleagues and hearing about new approaches in the field"

Hans Brightbill
Scientific Manager, Translational Immunology
Genentech

Conference Day Two
Thursday, August 29

Catch me in the Clinic
Capturing the Right Patients at the Right Time... as Quickly as Possible

8.30 Design of IPF Clinical Trials in the Era of Approved Therapies:

- Debating clinical trial design for Phase 1-3
- Endpoints to assess improvement in quality of life
- How to determine proof of concept from a phase 2 trial
- How is best to judge efficacy in phase 3

Panel Moderator:

Fernando Martinez
Chief, Division of Pulmonary & Critical Care Medicine
Weill Cornell Medicine

Panellists:

Robert Kaner
Associate Professor of Clinical Medicine
Weill Cornell

Majd Mouded
Medical Director, Clinical Development
Biogen

Ganesh Raghu
Director, Interstitial Lung Disease/ Sarcoid, Pulmonary Fibrosis Program
University of Washington

9.15 Think Tank Roundtable Discussions:

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendee to unite around hot topics, debate best practice and share experience to identify solutions.

In Vitro & In Vivo for Target Identification & Validation	Proof of Concept: Phase 2 Design	Novel Intermediate Outcomes Including Circulating Biomarkers & Biomarkers of Response

9.45 Roundtable Feedback Panel

10.15 Morning Break & Networking

Preclinical Stream

Cellular Senescence as a New Frontier & Pathological Feature for IPF

11.00 Challenges in Dissecting Protective from Disease-Driving Cell Senescence in IPF

- The accumulation and persistence of senescent cells is now a well-established feature of IPF
- The role of senescence in IPF is complicated because cell senescence can be organ protective via mitigation of tumor development, etc.
- Discussing strategies around distinguishing protective from disease-driving cell senescence

Cory Hogaboam, Professor of Medicine,
Cedars-Sinai Medical Center

Clinical Stream

Investigating Further Than IPF

11.00 Progressive Fibrosing ILD: An Extension of IPF?

- Sharing the concept of progressive fibrosing ILD in the context of IPF clinical trials
- Updates on ongoing clinical trials with anti-fibrotics in non-IPF lung disease

Kevin Flaherty, Division of Pulmonary & Critical Care Medicine, **University of Michigan**

11.30 Mechanisms of DNA Damage Response in the Lungs *In Vivo*

- Discussing the current paradigm between exposure to genotoxic stress, subsequent cellular senescence and lung fibrosis
- Assessing the relevance of *in vitro* findings to the *in vivo* context
- Revealing results and discussing relevance to human pathology and their translational opportunities

Andrei Gudkov, Professor of Oncology, **Roswell Park Comprehensive Cancer Center**

11.30 SSc-ILD Related Outcomes: Path to Proof of Concept in IPF

- SSc presents in skin and other tissues, including lung. Pre/post treatment skin biopsies can inform on target engagement in tissue
- Treating patients earlier in disease course may prevent progression to significant ILD
- Potential to get informative clinical outcomes in smaller, shorter trials than in IPF

Joe Arron, Senior Scientist & Senior Director, Immunology Discovery, **Genentech**

12.00 Targeting Cellular Senescence as a Therapeutic Approach for IPF

- Analyzing cellular senescence: from academic research to clinical trials
- Discussing induced senescence cells in IPF
- Reviewing current senolytic drugs development for IPF

Marc Ramis-Castelltort, Co-Founder & Chief Executive Officer, **Senolytic Therapeutics**

Evaluating Partnership & Collaboration Opportunities in IPF

12.00 IDL-2965: A Selective, Highly Potent, Clinical Stage Integrin Antagonist for the Treatment of IPF & NASH

- Discussing IDL-2965: an oral small-molecule integrin antagonist that potently inhibits αvβ1, αvβ3, and αvβ6
- Presenting IDL-2965 potent antifibrotic activity at low, once-daily, oral doses in multiple animal models of lung and liver fibrosis
- Sharing investigations of IDL-2965 in an adaptive, biomarker driven Phase 1/2a clinical program, allowing rapid progression from healthy volunteers to IPF and NASH patients

Karl Kossen, Senior Vice President of Translational Science, **Indalo Therapeutics**

12.30 Lunch & Networking

Gearing up for Phase 3, One Step at a Time: Providing Narrative Behind Results & Progress in Clinical Trials

Yves Wyckmans Senior Director, Corporate Business Development & Strategic Planning at Actelion **Janssen Pharmaceuticals**	**1.30 Perspectives for Partnerships Panel Discussion**
Rusty Montgomery Director, Research **Miragen Therapeutics**	**2.00 Next Generation miR-29 Mimics as a Therapy for Pulmonary Fibrosis** • Developing second generation miR-29 mimics with targeting capability • Understanding improved stability, retained miRNA activity and shown efficacy *in vivo* in bleomycin treated mice • Reviewing clinical viability including systemic administration at viable doses unlike previous versions
Wolfgang Jarolimek Head of Drug Discovery **Pharmaxis**	**2.30 Targeting Lysyl Oxidase Like 2 (LOXL2) to Treat IPF** • Scientific rationale for targeting LOXL2 • Presenting preclinical data supporting compound selection • Sharing clinical data for LOXL2 inhibitors
	3.00 Afternoon Break & Networking

Eric Lefebvre Chief Medical Officer **Pliant Therapeutics**	3.30	**PLN-74809, an Oral Dual Inhibitor of Integrins αVβ6 & αVβ1, for the Treatment of Idiopathic Pulmonary Fibrosis** • PLN-74809 was shown to be orally bioavailable and well tolerated in a Phase 1a single and multiple ascending dose study, with a long half-life supporting once-daily dosing • PLN-74809 is undergoing Phase 1b evaluation to assess its inhibitory effects on TGF-β activation, as measured by pSMAD levels in alveolar macrophages, collected via bronchoalveolar lavage • Phase 2a trials in IPF patients are planned for 2H19 and will include: PET imaging to assess target engagement of PLN-74809 on αVβ6 in lungs; a multinational dose-ranging safety, tolerability and PK study with exploratory endpoints including pulmonary function, biomarkers and imaging
Sonya Zabludoff Senior Director **Nitto Denko**	4.00	**Targeting the Collagen-Specific Chaperone, HSP47, with ND-L02-s0201, a Novel Lipid Nanoparticle Containing HSP47 siRNA, for the Treatment of Fibrotic Diseases** • Outlining HSP47 as a compelling anti-fibrotic target • Sharing of preclinical data supporting ND-L02-s0201 clinical development • Overview of on-going Phase 2 randomized, double blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and biological activity of ND-L02-s0201 in subjects with Idiopathic Pulmonary Fibrosis
Elias Kouchakji Senior Vice President, Clinical Development, Drug Safety & Pharmacovigilance **FibroGen**	4.30	**Directional Approach in Clinical Trials** • Additional data demonstrating improvement in quantitative lung fibrosis • Showing positive result in patient reported outcomes • Continuing phase 3 studies with patient reported outcomes
Fernando Martinez Chief, Division of Pulmonary & Critical Care Medicine **Weill Cornell Medicine**	5.00	**Chair's Closing Remarks**

"The IPF Summit brings together a unique group of translational researchers trying to solve the difficult problem of how to develop new therapies for IPF. The discussion is always vigorous and engaging - there's no other conference quite like it"

Joe Arron
Senior Scientist & Senior Director – Immunology Discovery
Genentech

"This is a fantastic forum to discuss the advances in preclinical research aimed at enhancing drug development for IPF"

Harry Karmouty-Quintana
Assistant Professor, Department of Biochemistry and Molecular Biology
UTHealth - McGovern Medical School

Partnership Opportunities

Why Partner?

The IPF Summit is your fastest route to organizations experienced in, and just starting to prioritize IPF and anti-fibrotic drug development.

Gathering stakeholders and key opinion leaders, this is your opportunity to position yourself at the front of the minds of 150+ drug developers from 100 organizations and elevate your company's standing and influence in this field.

We understand each business is different so we'll work with you to build a bespoke package to fulfil your 2019/2020 business objectives.

Whether that is presenting on the agenda, hosting networking sessions, exhibiting, or brand exposure, we have opportunities that offer it all.

Contact us to find out more – **sponsor@hansonwade.com**

Attending Seniority Breakdown from Previous IPF Summits



*Based on IPF Summit 2017 and 2018 statistics

Attending Companies Breakdown from Previous IPF Summits



*Based on IPF Summit 2017 and 2018 statistics

Previous Attending Companies:

ACTELION · AstraZeneca · Bellerophon THERAPEUTICS · bridgebio therapeutics · Celgene

COVANCE SOLUTIONS MADE REAL™ · Genentech A Member of the Roche Group · Kowa · LOVELACE BIOMEDICAL · LUPIN

MERCK · Metera PHARMACEUTICALS INC. · Nitto Innovation for Customers · PLIANT · Theravance Biopharma

Become a Partner

Jakub Nunuk
Partnership Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partners

Lead Partner

4Dx Limited is a medical technology company established to commercialize four-dimensional lung imaging technology: 4DxV. 4DxV provides a state-of-the-art, non-invasive way of understanding regional lung motion and airflow in real-time within the breathing lungs. This enables highly detailed maps of patterns of lung motion and pulmonary function, with functional deficits detected through local differences in movement. The end result: improving millions of lives through earlier disease detection and more accurate monitoring of chronic respiratory conditions.

www.4dx.com

Spotlight Partner

monARC Bionetworks is a healthcare technology company on a mission to modernize the clinical research industry by empowering patients to share their data and participate anytime, anywhere. By allowing patients to directly donate their data, monARC is creating a new data-sharing economy that will transform the highly sequential and siloed drug development model into an integrated and a collaborative model with patients.

www.monarcbio.com

Spotlight Partner

With an understanding that development of better medicine begins with better disease models, www.xylyxbio.com/ Xylyx Bio's native, disease-specific substrates enable cell models that are significantly more predictive of human pathophysiology, allowing drug candidates to be investigated *in vitro* in a disease-relevant environment. Xylyx products comprise the complex ratios of ECM components specific to each tissue/organ type and disease state and are available in a variety of formats to support high-throughput assays.

www.xylyxbio.com

Exhibition Partner

Aragen Bioscience is a leading contract research organization, focused on accelerating antibody and other large-molecule preclinical development. Our integrated service offerings include: cell line development, protein expression, protein purification, process development, cell-based assays, biophysical assays, and *in vivo* models of disease. We are based in the San Francisco Bay Area.

www.monarcbio.com

Become a Partner

Jakub Nunuk
Partnership Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.ipf-summit.com/register

Tel: +1 617 455 4188

Email: register@hansonwade.com

1. Investigate mechanisms of action of emerging therapeutics to contextualize and inform your own novel candidate decisions
2. More confidently and robustly evaluate systemic and imaging biomarkers to overcome diagnostic, prognostic, therapeutic and enrichment challenges and improve clinical attrition
3. Analyze fibrotic diseases beyond IPF including progressive and SSc-ILD to better understand how they can inform decisions for drug development in IPF

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Secure Your Place

Package Details	Register & Pay before Friday May 31 (Monday is a bank holiday)	Standard Prices
GOLD Conference & Workshop Day	$4296 **(save $700)**	$4696 **(save $300)**
SILVER Conference & 2 Workshops	$3797 **(save $500)**	$4097 **(save $200)**
BRONZE Conference Only	$2599 **(save $300)**	$2899
Workshops - individual	$699	

Venue

Sheraton San Diego Hotel & Marina
1380 Harbor Island Drive, San Diego
California, 92101, USA

For further information or assistance, please visit www.marriott.com/hotels/travel/sansi-sheraton-san-diego-hotel-and-marina/